COMP <GO>
BOLD vs ONCY // FORWARD P/E MULTIPLE
Boundless Bio Inc. (NASDAQ) VS. Oncolytics Biotech Inc. (NASDAQ) • 15-METRIC TALLY: BOLD 3
— ONCY 0
■ METRIC PARITY
LAST: $2.44 (-1.22%) • MKT CAP: $56.4M
forward-pe
—
LAST: $0.40 (-5.97%) • MKT CAP: $52.4M
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BOLD VS. ONCY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BOLD | ONCY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | BOLD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.9 | 21.1 | +22.80 | BOLD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $56.4M | $52.4M | $3.9M | BOLD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BOLD REV | ONCY REV | BOLD GROSS % | ONCY GROSS % | BOLD FCF | ONCY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $177.9M | $80.4M | — | — | -$47.2M | -$20.1M |
| FY 2024 | $205.1M | $71.5M | — | — | -$63.4M | -$20.1M |
| FY 2023 | $153.4M | — | — | — | -$46.9M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BOLD // BETA —
ONCY // BETA —